Clinical trials
Since POETIC's inception, two first-in-child clinical trials have been conducted increasing early access to novel molecularly targeted agents for treatment of children and adolescents with refractory malignancies after completion of adult Phase I studies. One of the studies resulted in evidence of clinical benefit in patients with tumors of the central nervous system using a novel agent targeting the epidermal growth factor receptor, cetuximab. These findings have provided the scientific rationale for a Phase II study targeting high grade central nervous system tumors, which is on-going.
Active clinical trials
Carfilzomib in combination with Cyclophosphamide and Etoposide for children
A Phase I study of Carfilzomib in combination With Cyclophosphamide and Etoposide for children with relapsed and refractory solid tumors and leukemias
Sponsor: Amgen
Protocol: POE14-01
Principal investigator: Jessica Boklan, MD
Site: Phoenix Children's Hospital
Estimated accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Safety and pharmacokinetics of Cobimetinib in pediatric and young adult participants with previously treated solid tumors
A Phase I/II study of Cobimetinib in patients with solid tumors
Sponsor: Genentech
Protocol: N/A
Principal investigator: N/A
Site: N/A
Estimated accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Idasanutlin in combination with either chemotherapy or Venetoclax in the treatment of pediatric and young patients with relapsed/refractory acute leukemias or solid tumors
Sponsor: Genentech
Protocol: GO40871
Estimated accrual years: 5 years (in 3 phases)
Read more about this trial at ClinicalTrials.gov
Safety and dose finding study of Neratinib in children and young adults with cancer that has returned or not responded to treatment
A Phase I/II study of Neratinib in pediatric patients with relapsed or refractory solid tumors or hematologic malignancies
Sponsor: Puma
Protocol: POE16-01
Principal investigator: Tanya Trippett, MD
Site: Memorial Sloan Kettering Cancer Center
Estimated accrual years: 1.0 (Phase I); 1.5 (Phase II)
Read more about this trial at ClinicalTrials.gov
Closed to accrual
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in patients with relapsed/refractory Ewing's Sarcoma and Neuroblastoma
A Phase II trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in patients With relapsed/refractory Ewing's Sarcoma and Neuroblastoma
Sponsor: N/A
Protocol: POE10-01
Principal investigator: Tanya Trippett, MD
Site: Memorial Sloan Kettering Cancer Center
Actual accrual years: 2.8
Read more about this trial at ClinicalTrials.gov
Clinical study of Vorinostat in combination with Etoposide in pediatric patients < 21 years at diagnosis With refractory solid tumors
A Phase I/II clinical study of Vorinostat in combination With Etoposide in pediatric patients < 21 Years at diagnosis with refractory solid tumors
Sponsor: N/A
Protocol: POE10-02
Principal investigator: Tanya Trippett, MD
Site: Memorial Sloan Kettering Cancer Center
Actual accrual years: 2.0 (Phase I); 2.4 (Phase II)
Read more about this trial at ClinicalTrials.gov
External beam radiation therapy and Cetuximab followed by Irinotecan and Cetuximab for children and young adults with newly diagnosed diffuse pontine tumors and high-grade astrocytomas
A Phase II trial of external beam radiation therapy and Cetuximab followed by Irinotecan and Cetuximab for children and young adults with newly diagnosed diffuse pontine tumors and high-grade astrocytomas
Sponsor: N/A
Protocol: POE08-01
Principal investigator: Ira Dunkel, MD
Site: Memorial Sloan Kettering Cancer Center
Actual accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Everolimus (RAD001) for children with chemotherapy-refractory progressive or recurrent low-grade gliomas
A Phase II study of Everolimus (RAD001) for children with chemotherapy and/or radiation-refractory progressive or recurrent low-grade gliomas
Sponsor: N/A
Protocol: POE09-01
Principal investigator: Mark Kieran, MD
Site: Dana-Farber
Actual accrual years: 2.1
Read more about this trial at ClinicalTrials.gov
Plerixafor as a chemosensitizing agent for relapsed acute leukemia and MDS in pediatric patients
A Phase I study using Plerixafor as a chemosensitizing agent for relapsed acute leukemia and MDS in pediatric patients
Sponsor: N/A
Protocol: POE10-03
Principal investigator: Todd Cooper, MD
Site: Children's Healthcare of Atlanta
Actual accrual years: 2.0
Read more about this trial at ClinicalTrials.gov
Phase I trial of Anti-PD-L1 in patients with solid tumors
A Phase I study of Anti-PD-L1 in patients with solid tumors
Sponsor: Genentech
Protocol: N/A
Principal investigator: N/A
Site: N/A
Estimated accrual years: 1.0
Completed studies
- Phase I trial of Cabazitaxel in patients with solid tumors including CNS
- Phase I trial of Cabazitaxel in patients with solid tumors including CNS
- Phase I trial of 17-AAG in patients with solid tumors and leukemia
- Phase I trial of Cetuximab and Irinotecan in patients with solid tumors including CNS
- Phase I trial of Oxaliplatin, Fluorouracil, and Leucovorin in patients with solid tumors
- Phase I trial of Clofarabine and Cyclophosphamide in patients with leukemia
- Phase I trial of Ridaforolimus in patients with solid tumors
- Safety and pharmacokinetics of Atezolisumb (MPDL3280A) in pediatric and young adults patients with previously treated solid tumors
Programs
Return to Top
Pediatric Oncology Experimental Therapeutics Investigators' Consortium
© Copyright 2021 | Website designed by Amanda M. Buckley